InsidersTradesSigma
Follow the 유바이오로직스 share price and the full management transaction log of the company, a publicly traded company based in South Korea. Shares are quoted on the KR market, under the oversight of DART (FSS). Operating in the Health Care sector, 유바이오로직스 has published 6 insider filings. Market capitalisation: €289bn. The latest transaction was reported on 6 July 2026 (Purchase). Among the most active insiders: 바이오노트. The full history is accessible without an account.
6
Insider Decl.
n/a
Thresholds
€3m
5 ops.
Buy Volume
n/a
n/a
Sell Volume
21Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 319 of 29,062 companies
86.9
score / 100
Value87
Quality87
FCF yld9.4%
Earn yld12%
EV/EBITDA5.3x
ROE·
Gross mgn58%
Net mgn28%
Debt/EBITDA0.1x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 6 July 2026
Declarations6 total
6 of 6 declarations
Acerca de 유바이오로직스
유바이오로직스 es una empresa farmacéutica y de atención médica que cotiza en el mercado XKRX. Se especializa en el desarrollo de productos biofarmacéuticos.